-+ 0.00%
-+ 0.00%
-+ 0.00%

ST Renfu announced on September 3 that the RFUS-949 tablets developed by its holding subsidiary Yichang Renfu have recently entered phase II clinical trial research. The drug is intended to be used to treat acute and chronic pain.

Zhitongcaijing·09/03/2026 08:41:07
Listen to the news
ST Renfu announced on September 3 that the RFUS-949 tablets developed by its holding subsidiary Yichang Renfu have recently entered phase II clinical trial research. The drug is intended to be used to treat acute and chronic pain.